Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Milan
Clinical trial register · Italy

Clinical Trials in Milan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 45 Rome 30 Naples 19 Rozzano 18 Bologna 15
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
IRCCS San Raffaele160 AstraZeneca138 Merck Sharp & Dohme LLC98 Hoffmann-La Roche81 Novartis Pharmaceuticals73 Clear sponsor filter
Site location
Milan45 Rome30 Naples19 Rozzano18 Bologna15
All 57 locations
Target enrolment
to

Trials with a site in Milan

45 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Active, closed
Sanofi
Phase 2
325
Milan
2026-05-19
Recruiting
Sanofi
Phase 2/3
526
Torette, Milan, Rome, Bologna, Brescia, Novara
2026-03-13
Recruiting
Sanofi
Phase 3
160
Milan, Foggia, Roma
2026-01-14
Recruiting
Sanofi
Phase 2
144
Torette, Cona, Garbagnate Milanese, Milan, Brescia, Chieti, Pisa
2025-12-29
Recruiting
Sanofi
Phase 3
85
Florence, Milan, Rozzano
2025-12-18
Recruiting
Sanofi
Phase 2
208
Milan, Catania, Roma
2025-11-06
Recruiting
Sanofi
Phase 3
60
Meldola, Milan, Naples, Torino, Vicenza
2025-10-24
Recruiting
Sanofi
Phase 2
54
Milan, Padua, Rome, Turin
2025-10-14
Recruiting
Sanofi
Phase 3
124
Florence, Milan, Verona
2025-09-26
Recruiting
Sanofi
Phase 3
942
Milan, Rozzano, Padova, Pavia, Reggio Emilia, Tradate (Va)
2025-09-16
Recruiting
Sanofi
Phase 2
30
Milan, Merano, Palermo, Pisa
2025-09-02
Recruiting
Sanofi
Phase 3
90
Florence, Genoa, Milan, Naples, Meldola, Novara, Palermo, Trieste
2025-08-18
Recruiting
Sanofi
Phase 3
192
Florence, Milan, Naples, Rome, Orbassano, Palermo, Verona
2025-08-12
Recruiting
Sanofi
Phase 3
723
Florence, Genoa, Milan, Rome, Turin, Bologna, Messina, Novara
2025-08-06
Active, closed
Sanofi
Phase 3
1,092
Rome, Bari, Foggia, Lecce, Milan, Parma
2025-05-22
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Genoa, Milan, Rozzano, Rome, Pavia, Pisa
2025-04-01
Active, closed
Sanofi
Phase 2
204
Genoa, Milan, Rozzano, Naples, Padua, Rome, Turin, Alessandria
2025-03-28
Active, closed
Sanofi
Phase 3
231
Cona, Florence, Genoa, Milan, Padua, Rome, Bologna
2025-02-12
Active, closed
Sanofi
Phase 3
216
Milan, Naples, Catania
2025-02-06
Active, closed
Sanofi
Phase 2
260
Milan, Rozzano, Padua, Rome, Pisa
2024-12-10
Active, closed
Sanofi
Phase 2
556
Torette, Monserrato, Cona, Genoa, Milan, Rozzano, Rome, Bergamo
2024-11-07
Active, closed
Sanofi
Phase 2
229
Milan, Padua, Pisa
2024-08-29
Recruiting
Sanofi
Phase 3
160
Milan, Rozzano, Padua, Bologna
2024-08-21
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Milan, Rozzano, Rome, Messina, Palermo, Pavia, Pisa
2024-07-12
Active, closed
Sanofi
Phase 3
1,541
Milan, Rozzano, Rome, Bologna, Catania, L’Aquila, Pisa, Vicenza
2024-05-08
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Pozzilli, Milan, Rome, Florence, Bergamo, Cagliari, Catania, Chieti
2024-04-16
Active, closed
Sanofi
Phase 3
260
Torette, Genoa, Milan, Rozzano, Rome, Turin, Bergamo, Bologna
2024-01-23
By invitation
Sanofi
Phase 3
90
Milan, Padua, Rome, Naples, Pavia
2024-01-03
Active, closed
Sanofi
Phase 3
943
Augusta, Cona, Florence, Genoa, Milan, Naples, Cefalù, Rome
2023-12-27
Active, closed
Sanofi
Phase 3
1,655
Cona, Florence, Genoa, Milan, Monza, Naples, Rome, Orbassano
2023-12-13
Active, closed
Sanofi
Phase 2
197
Torette, Florence, Milan, Naples, Rome, Novara, Varese, Verona
2023-12-11
Recruiting
Sanofi
Observational
230
Bologna, Brescia, Florence, Milan, Naples, Roma, Verona
2023-11-30
Recruiting
Sanofi
Phase 3
180
Milan, Padua, Palermo, Pavia, Siena
2023-10-10
Active, closed
Sanofi
Phase 2
999
Milan, Naples, Rome, Brescia, Vicenza
2023-04-03
Active, closed
Sanofi
Phase 3
91
Rozzano, Milan
2023-02-01
Active, closed
Sanofi
Phase 2
187
Bolzano, Milan, Rozzano, Rome, Catanzaro, Palermo, Pavia
2022-11-25
Active, closed
Sanofi
Phase 2/3
1,856
Milan, Rozzano, Naples, Rome, Turin, Bologna, Catania, Chieti
2022-08-22
Active, closed
Sanofi
Phase 2
48
Bologna, Rome, Brescia, Milan
2022-06-09
Active, closed
Sanofi
Phase 3
104
Milan, Naples, Bologna
2022-05-03
Active, closed
Sanofi
Phase 3
43
Milan, Naples
2022-04-18
Recruiting
Sanofi
Phase 3
284
Cona, Florence, Milan, Rozzano, Naples, Rome, Ancona
2022-02-15
Active, closed
Sanofi
Phase 2
22
Avellino, Meldola, Milan
2021-12-07
Active, closed
Sanofi
Phase 2
109
Milan, Rome
2021-11-10
Active, closed
Sanofi
Observational
1,860
Terracina, Naples, Padua, Bari, Bologna, Brescia, Catania, Milan
2019-08-15
Recruiting
Sanofi
Phase 2
51
Genoa, Milan, Rome
2018-08-09
Rows per page Showing 1–45 of 45
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-italy/city/milan

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 45 of those studies with a site in Milan that also match the filters currently applied.

How many clinical trials are recruiting in Milan?

18 of the 45 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 25 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Milan), 45 studies
PhaseStudiesRecruitingShare
Phase 3251155.6%
Phase 216535.6%
Observational214.4%
Phase 2/3214.4%

Most active sponsors

Lead sponsors with the most studies (Milan)
Lead sponsorStudiesRecruiting
Sanofi4518
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.